Invivyd (IVVD)

Executive Summary

Invivyd (NYSE: IVVD) is a publicly traded biopharmaceutical company focused on developing rapidly adaptable monoclonal antibody therapies to combat evolving viral threats, primarily COVID-19. Leveraging its proprietary viral surveillance and antibody engineering platform, the company aims to outpace viral evolution. Despite early setbacks with ADG20, which was terminated in Phase 2/3, Invivyd has advanced its lead candidate, VYD2311, into a Phase 3 clinical trial (NCT07298434) evaluating multiple doses for COVID-19, with completion expected by June 2026. The company also completed Phase 3 trials for pemivibart (VYD222), which may support regulatory pathways. As of early 2026, Invivyd holds a market valuation of approximately $397 million, reflecting cautious investor sentiment given the competitive COVID-19 therapeutic landscape and past clinical failures. However, the company’s focus on next-generation antibodies positions it to capitalize on emerging SARS-CoV-2 variants and potential future viral threats.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 topline data readout for VYD2311 in COVID-1965% success
• Q4 2026Potential EUA or regulatory filing for VYD2311 based on Phase 3 data40% success
• TBDExpansion of pipeline into new viral indications via platform technology30% success